Naltrexone

Alcohol use disorder (AUD) is one of the most prevalent substance use disorders in the US. Effective medications for AUD (MAUD) have been available for over 40 years; however, less than 1 percent of individuals with AUD receive them. A recent systematic review of studies lasting ≥12 weeks described the effects on alcohol consumption of […]

Key Points Question: Which pharmacotherapies are associated with improved outcomes for people with alcohol use disorder? Findings: In this systematic review and meta-analysis that included 118 clinical trials and 20 976 participants, 50 mg/d of oral naltrexone and acamprosate were each associated with significantly improved alcohol consumption-related outcomes compared with placebo. Meaning:  These findings support oral naltrexone at

Oral naltrexone has been shown to reduce alcohol consumption and craving in individuals with alcohol use disorder (AUD), yet evidence regarding the efficacy of the extended-release injectable formulation (XR-naltrexone) is limited. Researchers conducted a systematic review and meta-analysis of 7 randomized controlled trials evaluating 1500 adults with AUD receiving XR-naltrexone (150–400 mg) for 2–6 months

Amphetamines are the second-most commonly used drug in the world and their use is rising in the US. There are currently no FDA-approved medications for treating methamphetamine use disorder (MUD). This multisite randomized controlled trial evaluated the efficacy and safety of extended-release naltrexone (380mg every 3 weeks) plus oral extended-release bupropion (450mg daily), compared with

Researchers have begun testing drugs approved for other substance use disorders to treat people with methamphetamine addiction. Examples include naltrexone—which is used for the treatment of opioid use disorder—and bupropion, which helps people quit smoking. Both treatments have shown some effectiveness when used alone to treat methamphetamine addiction. A research team led by Dr. Madhukar

New England Journal Medicine Among adults with methamphetamine use disorder, the response over a period of 12 weeks among participants who received extended-release injectable naltrexone plus oral extended-release bupropion was low but was higher than that among participants who received placebo. (Funded by the National Institute on Drug Abuse and others; ADAPT-2 ClinicalTrials.gov number, NCT03078075..)

The misuse of this term ‘overdose’ is quite common in the illicit drug use culture, and it has become synonymous with an event where a drug user has died or come very close to death and has had to receive urgent medical attention or even been hospitalized to prevent death, as a result of taking

The Perth-based doctor who pioneered a naltrexone implant to address drug addiction has been awarded a $US20 million ($28.6m) grant to trial his innovation in the US, which is dealing with an opioid epidemic. Download PDF